<DOC>
	<DOC>NCT00838201</DOC>
	<brief_summary>The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.</brief_summary>
	<brief_title>Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Subjects must be currently participating in the 20040138 Amgen study Subjects must sign the informed consent before any study specific procedures are performed. Exclusion Criteria Subjects with any prior diagnosis of bone metastasis Known hypocalcemia Developed sensitivity to mammalian cell derived drug products during the 20040138 study Currently receiving any investigational product other than denosumab or having received any investigational product during the 20040138 study Any disorder that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent and/or comply with study procedures</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Androgen deprivation therapy for non-metastatic prostate cancer</keyword>
</DOC>